title: Adjuvant treatment of melanoma using placebo or no therapies as control-arm: is it ethically correct?
authors.forename: P A
authors.initials: PA
authors.lastname: Ascierto
authors.forename: A
authors.initials: A
authors.lastname: Daponte
authors.forename: P
authors.initials: P
authors.lastname: Giuseppe
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D019496:Cancer Vaccines / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D018572:Disease-Free Survival; D004992:Ethics, Medical; D006801:Humans; D007167:Immunotherapy; D007372:Interferons / Q000008:administration & dosage; D008545:Melanoma / Q000401:mortality / Q000628:therapy*; D012878:Skin Neoplasms / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D017778:Vaccines, Combined
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D017778:Vaccines, Combined; C094534:polyvalent melanoma cell vaccine; D007372:Interferons